ClinVar Miner

Submissions for variant NM_000263.4(NAGLU):c.1834A>G (p.Ser612Gly) (rs148881970)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Fulgent Genetics,Fulgent Genetics RCV000686454 SCV000894120 likely pathogenic Mucopolysaccharidosis, MPS-III-B; Charcot-Marie-Tooth disease, axonal type 2V 2018-10-31 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000625994 SCV000914767 pathogenic Mucopolysaccharidosis, MPS-III-B 2018-11-01 criteria provided, single submitter clinical testing The NAGLU c.1834A>G (p.Ser612Gly) variant has been reported in four studies and in a total of 11 probands with mucopolysaccharidosis including ten probands in a compound heterozygous state and one proband in a homozygous state (Zhao et al. 1998; Verhoeven et al. 2010; Valstar et al. 2010; Selmer et al. 2012). Segregation analysis confirmed co-segregation with disease in a clear autosomal recessive inheritance pattern in two families (Zhao et al. 1998; Selmer et al. 2012). Control data are unavailable for this variant, which is reported at a frequency of 0.00022 in the European (non-Finnish) population of the Exome Aggregation Consortium. Two studies demonstrated deficient alpha-N-acetyl glucosaminidase (NAGLU) enzyme activity in cultured fibroblasts from affected subjects (Verhoeven et al. 2010; Selmer et al. 2012). In five of the six families reported, this variant was associated with an attenuated phenotype of MPS IIIB with a slower progression of disease. Based on the collective evidence the p.Ser612Gly variant is classified as a pathogenic variant for mucopolysaccharidosis type III. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV000686454 SCV000813973 pathogenic Mucopolysaccharidosis, MPS-III-B; Charcot-Marie-Tooth disease, axonal type 2V 2018-09-11 criteria provided, single submitter clinical testing This sequence change replaces serine with glycine at codon 612 of the NAGLU protein (p.Ser612Gly). The serine residue is moderately conserved and there is a small physicochemical difference between serine and glycine. This variant is present in population databases (rs148881970, ExAC 0.02%). This variant has been reported in individuals affected with a mild form of mucopolysaccharidosis type IIIB (PMID: 9443875, 20852935, 217121855, 25256447, 26907177). Experimental studies have shown that cells derived from an individual with this variant and a second missense variant in trans had very low residual NAGLU enzyme activity (PMID: 21712855). For these reasons, this variant has been classified as Pathogenic.
Undiagnosed Diseases Network,NIH RCV000625994 SCV000746600 pathogenic Mucopolysaccharidosis, MPS-III-B 2017-02-09 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.